Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The NPM-ALK oncoprotein abrogates CD30 signaling and constitutive NF-kappaB activation in anaplastic large cell lymphoma.

Cancer cell - 1 Apr 2004

Horie Ryouichi, Watanabe Mariko, Ishida Takaomi, Koiwa Tsukasa, Aizawa Shigemi, Itoh Kinji, Higashihara Masaaki, Kadin Marshall E, Watanabe Toshiki

Abstract excerpt

NPM-ALK characterizes anaplastic large cell lymphoma (ALCL), as does the high expression of CD30, a feature shared with H-RS cells of classic Hodgkin's lymphoma. In H-RS cells, ligand-independent signaling by overexpressed CD30 drives constitutive NF-kappaB activation, which is absent in ALCL cells. Here we show that NPM-ALK impedes CD30 signaling and NF-kappaB activation, dependent on both ALK kinase activity...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Consensus Sequence
Share to Electrophoretic Mobility Shift Assay

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to I-kappa B Proteins

Share to Ki-1 Antigen

Share to Lymphoma, Large-Cell, Anaplastic

Share to Oncogene Proteins, Fusion

Share to TNF Receptor-Associated Factor 2

Share to Tyrosine

Source

Identifiers

PMID: 15093542
DOI: 10.1016/s1535-6108(04)00084-4

Genes

ALK
TRAF2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The NPM-ALK oncoprotein abrogates CD30 signaling and constitutive NF-kappaB activation in anaplastic large cell lymphoma.PMID 15093542Read ↗

The proteomic signature of NPM/ALK reveals deregulation of multiple cellular pathwaysSemantic proximity Read ↗

Ablation of oncogenic ALK is a viable therapeutic approach for anaplastic large-cell lymphomasSemantic proximity Read ↗

NPM-ALK oncogenic tyrosine kinase controls T-cell identity by transcriptional regulation and epigenetic silencing in lymphoma cells.Semantic proximity Read ↗

Translocations involving anaplastic lymphoma kinase (ALK).Semantic proximity Read ↗

Inhibition of ALK Signaling for Cancer TherapySemantic proximity Read ↗

The Potent Oncogene NPM-ALK Mediates Malignant Transformation of Normal Human CD4+ T LymphocytesSemantic proximity Read ↗

Identification and characterization of a nuclear interacting partner of anaplastic lymphoma kinase (NIPA).Semantic proximity Read ↗

Ligand-independent signaling by overexpressed CD30 drives NF-kappaB activation in Hodgkin-Reed-Sternberg cells.Semantic proximity Read ↗

Anaplastic Lymphoma Kinase (ALK) Receptor Tyrosine Kinase: A Catalytic Receptor with Many FacesSemantic proximity Read ↗

Gene expression profiling of isolated tumour cells from anaplastic large cell lymphomas: insights into its cellular origin, pathogenesis and relation to Hodgkin lymphoma.Semantic proximity Read ↗

Anaplastic lymphoma kinase: signalling in development and diseaseSemantic proximity Read ↗

De novo generation of the NPM-ALK fusion recapitulates the pleiotropic phenotypes of ALK+ ALCL pathogenesis and reveals the ROR2 receptor as target for tumor cells.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.